Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review

M.A. Munir a, b, *, P.A. Tandiabang c, T. Setyawati d, A. Basry d, A.D. Cyio e, N. Rahman f

a Department of Bioethics, Humanities and Social Health Science, Faculty of Medicine, Tadulako University, Palu, Indonesia
b Department of Orthopaedic and Traumatologiy Surgery, Undata General Hospital, Palu, Indonesia
c Department of Anatomy, Faculty of Medicine, Tadulako University, Palu, Indonesia
d Medical Profession Program, Faculty of Medicine, Tadulako University, Palu, Indonesia
e Department of Social Sciences, Faculty of Humanities and Social Sciences, Tadulako University, Palu, Indonesia
f Department of Statistics, Faculty of Mathematics and Natural Science, Tadulako University, Palu, Indonesia

A R T I C L E   I N F O

Article history:
Available online 8 April 2021

Keywords:
Bioethical perspective
Convalescent plasma
SARS-CoV-2
COVID-19

A B S T R A C T

Convalescent plasma therapy (CP) has long been used to prevent and treat various infectious diseases before COVID-19 such as SARS, MERS, and H1N1. Because the viral and clinical characteristics of COVID-19 share the similarities between SARS and MERS, CP treatment could be a promising treatment option to save COVID-19. With only low quality medical evidence, but massive media support and a very significant public demand for the use of convalescent plasma for COVID-19, we are now faced with an ethical dilemma. Therefore, this paper uses a structured analysis that focuses on the preferred reporting items for a systematic review of ethical issues regarding the use of Convalescent Plasma Therapy for COVID-19. The use of convalescent plasma must meet the ethical principles of autonomy; such as voluntary, informed consent, and confidentiality. Consideration of the risk-benefit ratio for potential donor recipients also needs to be considered in order to meet the beneficence and non-maleficence principles. The principle of justice also needs to be applied both to donors, donor recipients and health workers, such as determining the priority of donor recipients, due to the increasing demand for convalescent plasma amid the limited circumstances of patients who have recovered from Covid-19 who voluntarily donate.

© 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

After the 11 March 2020 pandemic declaration, Coronavirus Disease 2019 (COVID-19) patients continued to increase [1]. More than 30 million people worldwide have suffered from COVID-19 by the end of September 2020 [2–4]. To date, there are no options for SARS – CoV-2 exposure prophylaxis [5]. The World Health Organization (WHO) and other clinical institutions have not established a definite treatment for this disease, because specific treatments are still under study [6,7]. Antiviruses, such as favipiravir, oseltamivir, are used, but patient responses to receiving these drugs are mixed. Even though the death rate from COVID-19 is around 3–4%, because the number of cases is very high, this is a big problem [2,8].

Convalescent plasma therapy (CP), has long been used to prevent and treat many infectious diseases before COVID-19 [9]. In the last two decades, this CP therapy has been used successfully in treating the SARS, MERS, and H1N1 epidemics with patient efficiency and safety [10]. Because the viral and clinical characteristics of COVID-19 have similarities between SARS and MERS [11], CP treatment could be a promising treatment option to save COVID-19 [6,12].

With only low quality medical evidence, but massive media support and a very significant public demand for the use of convalescent plasma for COVID-19, we are now faced with an ethical dilemma. The huge public demand for the use of CP is causing immense and inexorable pressure on physicians who treat patients and administrators have complied with this demand and are committed to only compassionately using convalescent plasma [12,13]. This document specifically analyzes the bioethical issues surrounding the potential use and study of convalescent plasma therapy in COVID-19.

* Corresponding author. Department of Bioethics, Humanities and Social Health Science, Faculty of Medicine, Tadulako University, Palu, Indonesia.
E-mail address: adimunirunitad@gmail.com (M.A. Munir).

https://doi.org/10.1016/j.traci.2021.03.005
1246-7820 © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Methods

Several search strategies were used to identify relevant studies. Search for data and information using electronic sites as data sources. In the search results, articles that are not relevant to the criteria for identification, screening, eligibility, and finally downloading of the relevant articles are carried out.

Document selection using the keywords “Convalescent Plasma Therapy in COVID-19” and “Ethics for Convalescent Plasma Use” in the journal Scopus, Springer, Database Sciencecite/Elsevier, NCBI, NEJM, Nature, Wiley, Oxford academy. Researchers found 1,246 documents based on full text access to free or paid documents and English-based documents. Then re-selection of journals based on titles and abstracts into 250 documents, then found 30 documents that meet the research criteria and 1 national health regulation in Indonesia, then these documents are analyzed.

The document inclusion criteria that we consider appropriate for conducting a systematic review are research journals, reported in English, relevant and reliable discussing the Ethics of Convalescent Plasma Use. Studies are excluded if they are inaccessible, lack reliable references, and are expensive.

3. Result and discussion

Convalescent plasma (CP) therapy is suggested to be used as an adjunctive treatment for COVID-19 [14]. This approach was used in Ebola, Middle East respiratory syndrome (MERS) and severe acute respiratory coronavirus (SARS-CoV) infection, and several studies showed promising results. Convalescent plasma therapy works to decrease the viral load, cytokine response, and mortality rate. In addition, CP therapy also works by transferring antibody of a certain infectious agent from survivors to patients who are infected with the same agent of disease. This form of passive immunity helps the patient to fight the disease from getting worse immediately [5]. CP has been used in a small population of clinically severe COVID-19 patients [15], and promising results are seen in this population [16].

First of all, it is important to understand the types of resources we are talking about, why they are needed at a vital level, and what it means to be a donor. Blood is a fluid network that is essential for life and can cure very serious diseases, such as in this case COVID-19, but it can also be the cause. It is important to imitate blood collection and management, not forgetting that the goal is not to be lucrative, but to curative [17].

COVID-19 recovery plasma can be experimentally available through local production, provided that ethical and safety standards are met for preparation and use. Blood management systems that provide COVID-19 recovery plasma must ensure that blood companies have adequate capabilities to collect, process and store this particular product in a manner that is quality assured according to the World Health Organization and other internationally recognized standards for plasma transfusion [18].

The limited clinical data available suggests that healing plasma (CP) may have therapeutic benefits in COVID-19 [19]. There is no known effective therapy and considering local production potential, CP of COVID-19 is becoming a global priority for investigative use. This has a devastating effect on the blood supply and blood components in many countries through the reduction of blood donations and disruption of routine practices in blood companies. Blood services around the world must move quickly in response to a pandemic to maintain adequate blood for the critical needs of patients, ideally through developing, implementing and activating emergency response plans in collaboration with hospitals [18]. High-income countries with established national infrastructures and effective regulatory oversight can produce quality and safe plasma for transfusion that complies with international standards and have initiated controlled clinical studies of COVID-19 CP [20].

Unfortunately, in low and middle income countries (LMICs) safe blood collection and transfusion is a challenge due to the absence of a nationally organized and regulated blood collection system and the limitations of essential resources and labor. Nonetheless, the provision of CP for COVID-19 at LMICs must meet the same principles of product safety and ethics regarding collection and use as at HIC, and guidelines are required [5].

There are interim guidelines provided by WHO on “Maintaining a safe and adequate blood supply during the Coronavirus (COVID-19) pandemic on March 20, 2020. Recently, on July 10, 2020, WHO published updated interim guidelines entitled “Guidance on Keeping a Safe and enough blood supply during the 2019 coronavirus disease (COVID-19) pandemic and collection of COVID-19 convalescent plasma”. These updated interim guidelines by WHO provide greater detail on the management of blood supply and expanded recommendations on the collection of plasma recovered from COVID-19 compared to previous versions [18], these guidance can be seen in (Table 1).

The use of convalescent plasma must fulfill the ethical principles of autonomy, nonmaleficence, beneficence, justice and respect for people.

3.1. Donor-related issues

3.1.1. Autonomy

3.1.1.1. Voluntariness. All blood and plasma donors must be voluntary and unpaid [21]. This highly voluntary approach to blood donation is consistent with emphasizing the importance of altruistic donation of donors and the principle of human dignity insofar as it does not use the human body or its parts as a source of financial gain [22]. Identifying donors in health facilities, willing to volunteer to donate plasma once they have fully recovered, should be done in a way that does not apply undue pressure.

3.1.1.2. Obtaining informed consent. Potential donors should be well informed about the reasons for donating their blood or plasma, the potential benefits and risks associated with this procedure to them so that they can make an informed decision. If possible, potential donors should also be notified that they can be contacted again for further donations informed that potential donors may not be suitable after certain tests or screening may be needed to confirm the usefulness of donor plasma [23].

3.1.1.3. Avoiding coercion and exploitation. Respecting donor autonomy also means that potential donors should not be coerced or exploited. In the context of donating convalescent plasma, coercion refers to the act of threatening people who have recovered from COVID-19 regardless of their health status. Whereas exploitation refers to any practice that leads to an unfair distribution of burdens and benefits from donations. An example of exploitation is receiving recurring donations from a single person who has recovered from COVID-19 regardless of their health status [23].

3.1.2. Fair selections of donor

Donation of convalescent plasma from patients who have recovered from COVID-19 can only be accepted if the donation is deemed safe for donors and mechanisms to guard against exploitation of potential donors are strictly assessed by competent health workers [23].

3.1.2.1. Children. Because children are at high risk for vasovagal reactions and adolescents have a higher need for iron, children who have recovered from COVID-19 should in principle be excluded from donations (in accordance with WHO guidelines for donor
Mitigating the potential risk of transmission through the transfusion of blood and blood components

Mitigating the risk of staff and donor exposure to SARS-CoV-2

Mitigating the impact of reduced availability of blood donors

Managing the demand for blood and blood products

Ensure undisturbed supplies of critical material and equipment

Communication

Collection of COVID-19 convalescent plasma

| Goals | Ethical procedure |
|-------|-------------------|
| Mitigating the potential risk of transmission through the transfusion of blood and blood components | Potential blood donors should be told that they need to postpone on the basis of risk factors for COVID-19 or feel dissatisfied. In areas where the SARS-CoV-2 population is common, blood donors should be advised to alert the blood center if respiratory diseases grow within 14 days of donation. People with potential direct exposure to SARS-CoV2 should not give blood for a period of time when they have been near in contact with infected patients and move from areas with population transmission. People who tested SARS-CoV-2 positively but never had symptoms should delay 14 days after the last positive test. Persons that have recovered from COVID-19 should be deferred from normal blood donation for 14 days after total symptom resolution and cessation of disease therapy. Donor postponement can take the form of a self-delay or postponement by a blood collection facility. Due to the lack of a future illness identified to donors, a quarantine of delayed release components is possible during transition to the population. A mechanism should be in place for donors to disclose a COVID-19 compatible post-donation disease or interaction with a reported post-donation case. Blood supply checks are too early if there are no cases of transfusion or if there are SARS-CoV-2 blood infections obtained from asymptomatic patients, including people with earlier symptoms. Pathogen reduction technologies (PRTs) have demonstrated their effectiveness in both SARS-CoV and MERS-CoV plasma and thrombosis. Current plasma derivatives development processes can disable and eradicate enveloped viruses such as SARS-CoV-2. There is therefore no alleged risk of transmission through this product. The hemovigilance system relies on the capacity of an individual to use these components. Hemovigilance is invaluable because it helps to consider the toxicity of blood and its components and the potency of the whole blood [17]. |
| Mitigating the risk of staff and donor exposure to SARS-CoV-2 | Minimize interaction between donors and workers, decontaminate the area on a regular basis. Measurement of temperature at arrival, facial masks, hand sanitization and physical isolation of incoming donors [18]. Workers should be trained and aware about COVID-19 if they feel diseased or are exposed to it [18]. |
| Mitigating the impact of reduced availability of blood donors | Because mobile donation activities have been reduced as a result of the closure of workplaces, schools and community organizations, strategies that could be used include rapid movements to places to draw blood, donor transportation, increased effort to schedule donation rates or adjustment of operating times. Governments should recognize blood donation as an important service and provide frameworks to ensure that donors are not penalized for donating. Systems need to be in place to allow contaminated donors to re-enter after recovery. Importing blood and components from a non-affected nation or country region (where approved by regulatory bodies) is a possible solution if insufficient local stocks. Blood services must regularly monitor their blood supply so that the size of collection operations can be expected unpredictable. Blood transfusions are also required in emergencies including trauma, postpartum hemorrhage, serious infant anemia, blood dyscrasia, or urgent blood surgeries. Increased stock may also be required to support COVID-19 patients with serious sepsis or to support oxygenation of an extracorporeal membrane. Blood services should collaborate and clearly coordinate with the health professionals responsible for transfusion operations in order to ensure that blood and components are only used where they are clinically suitable [19]. |
| Managing the demand for blood and blood products | The global supply network of vital materials and equipment used in the collection of blood, components and laboratory tests (including immunohematologic reagents and infectious disease tests) which be reduced by transportation and trade constraints, quarantine requirements, border control and development disturbances. Blood services must take action to ensure supply stability. Governments and blood services can clearly communicate to ensure national emergency response teams, donors and beneficiaries and the public are adequately advised and recognize the action planned, including acknowledgement of the activities of blood collection as an indispensable service [20]. |
| Ensure undisturbed supplies of critical material and equipment | Qualification based on normal blood or plasma donation requirements. Diagnostic confirmation of previous SARS-CoV-2 infection. Total symptom resolution and discontinuation of COVID-19 therapy at least 14 days before donation. The minimum neutralizing antibody titer required for plasma to be used as convalescent plasma Measurement of the titration of the neutralizing antibody in the plasma convalescent device. |

3.1.2.2 Other persons with diminished autonomy. Potential donors with disabilities, such as individuals with moderate or recurring mental health problems, must consider the following: (1) an assessment of their ability to give consent for the donation process, including blood tests for heirs [24], and (2) there are sufficiently strong mechanisms to ensure that potential donors, with reduced autonomy, are not forced to donate or submit to exploitative practices. If the above criteria are met, individuals with low autonomy and family members or legal representatives must give the appropriate consent [25].

3.1.3. Confidentiality

In Indonesian, if we look at it from a legal point of view, then medical secrets can be revealed in a number of circumstances. According to PMK Number 36 of 2012 concerning Medical Secrets, there are several conditions that allow doctors or health workers to disclose medical secrets, namely for the benefit of the patient’s health, in the context of law enforcement, at the request of the patient himself and for the public interest, one of which is when
there is a threat of an outbreak [26]. However, in conditions of blood donation, the identities of people who have recovered from COVID-19 must be carefully protected from wider disclosure to protect the freedom of individuals to refrain from donations. Likewise, transfusions must be anonymous, which means that the identities of donors and recipients must be kept confidential. To do this, sites should consider storing donated blood and plasma rather than conducting a one-to-one transfusion service by donating blood or plasma directly to a specific person such as a family member or friend. To further protect donor confidentiality, care centers should store blood and plasma units using only ID numbers instead of identifiable information and ensure adequate disposal of unused units. Access to areas where confidential records of donors, patients or staff are kept should be limited to authorized staff [27].

3.2.1.3. Maintaining a positive risk–benefit ratio for recipients. Ethically, the risk of being exposed to people with COVID-19 should be minimized as much as possible. Given the uncertain effectiveness of using recovery plasma in treating patients with COVID-19 and given the prevalence of transfusion–transmissible infections in communities where the COVID-19 pandemic is occurring, no shortcuts should be taken in screening donor blood for other infections and residual marks. Sars-CoV-2 infectivity (e.g., RT-PCR not infectivity). Adhering to safety standards avoids adding risk to unknown benefit interventions and thus maintains a positive benefit - a balance of risks. Therefore, implementation of strict protocols to ensure compatibility between donor and recipient and safety regarding transmissible infections is mandatory. Developing a warning system to monitor, investigate, manage and record any adverse transfusion events is also highly recommended [23].

3.2.2. Fair selection of people with COVID-19

The priority of patients receiving healing plasma therapy should be consulted, as the need for recovery plasma exceeds the available supply. On the other hand, consideration of equality suggests that those who are sicker or those who are more vulnerable, such as pregnant women, children with mental disabilities and those with low autonomy, should not be excluded from this intervention.

In determining priority recipients, the community and stakeholders must be involved. Priority setting must prioritize the principle of justice, where all beings are equal [31]. However, in this process it must be seen from the patient’s clinical condition, and the main priority is the COVID-19 patients who are most likely to benefit from the intervention, or those who are most likely to benefit from this treatment, in accordance with the principle of triage in disaster conditions [32]. The process used to develop priority setting criteria should be fully transparent and involve the governments of affected countries or their representatives, panels of experts in infectious diseases, treatment and transfusion ethics and communities in a participatory and inclusive manner to avoid creating perceptions of unfair allocations, frustration or community mistrust towards the health system and health actors, national and/or international.

3.3. Issues related to health workers and research and ancillary staff

Staff working at donation and care sites need to be provided with adequate safety standards, including appropriate personal protective equipment, as any action related to blood, of course, carries several types of risks. Health care workers also need to be specially trained in standard international procedures to prevent transmission of Sars–CoV-2 and to treat patients with COVID-19 with whole blood and recovered plasma.

HCWs, researchers and ancillary personnel also need to be adequately informed about the risks of their possible procedures and agree to implement these interventions, whether they are part of the study or part of the monitored emergency use of unregistered and experimental interventions. However, the risks associated with this procedure need to be minimized to the greatest extent possible.

4. Conclusion

The use and preparation of convalescent plasma for COVID-19 must be supervised by the Ministry of Health and must be
coordinated with the National Blood Service and must comply with legal principles and human research ethics that apply to COVID-19. The use of convalescent plasma must meet the ethical principles of autonomy; such as voluntary, informed consent, and confidentiality. Consideration of the risk-benefit ratio for potential donor recipients also needs to be considered in order to meet the beneficence and non-maleficence principles. The principle of justice also needs to be applied both to donors, donor recipients and health workers, such as determining the priority of donor recipients.

Disclosure of interest

The authors declare that they have no competing interest.

Acknowledgments

The authors express gratitude to the International Publication & Collaborative Center (IPCC) Team of Tadulako University for their assistance in completing this journal and the students of the Faculty of Forestry of Tadulako University for their support in collecting the field data.

References

[1] WHO. Rolling updates on coronavirus disease (COVID-19). WHO; 2020.
[2] ArCGIS. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE). Johns Hopkins University; 2020.
[3] Mahapatra S, Pati S. Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic-strategies and recommendations to overcome these. Transfus Clin Biol 2021, http://dx.doi.org/10.1016/j.trabc.2021.02.003 [p. S1246782021000367].
[4] Padhi S, et al. ABO blood group system is associated with COVID-19 mortality: an epidemiological investigation in the Indian population. Transfus Clin Biol 2020;27:253–8, http://dx.doi.org/10.1016/j.trabc.2020.08.009.
[5] Bloch EM, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757–65, http://dx.doi.org/10.1172/JCI138745.
[6] Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398–400, http://dx.doi.org/10.1016/S1473-3099(20)30141-9.
[7] Moran HK, Brooks JV, Spoozak L. Undergoing active treatment for gynecologic cancer during COVID-19: a qualitative study of the impact on healthcare and social support. Gynecol Oncol Rep 2020;34:100659, http://dx.doi.org/10.1016/j.gore.2020.100659.
[8] Mehta RM, Bansal S, Bysani S, Kalpakam H. A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real-world analysis. Int J Infect Dis 2021, http://dx.doi.org/10.1016/j.ijid.2021.02.092 [p. S12019771221001788].
[9] Hung IF, et al. Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clin Infect Dis 2011;52:447–56, http://dx.doi.org/10.1093/cid/ciq106.
[10] Cheng Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24:44–6, http://dx.doi.org/10.1007/s10096-004-1271-9.
[11] Lee P-I, Hsuheh P-R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect 2020;53:365–7, http://dx.doi.org/10.1016/j.jmiij.2020.02.001.
[12] Vlahogianni G, Hassapopoulou-Matamis H, Politis C, Fylaki E, Mentis A. A case of COVID-19 Convalescent Plasma Donation in Greece: directed donation (compassionate use) in the Greek Red Cross. Transfus Clin Biol 2020;27:269–70, http://dx.doi.org/10.1016/j.trabc.2020.09.001.
[13] Johnson S. COVID-19 and convalescent plasma: when compassion and ethics are in conflict. BMJ J 2020.
[14] Guan W, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708–20, http://dx.doi.org/10.1056/NEJMoa2002032.
[15] Shen C, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582, http://dx.doi.org/10.1001/jama.2020.4783.
[16] Putera DD, Hardianti MS. Efficacy and safety of convalescent plasma therapy in patients with COVID-19: a rapid review of case series. J Med Sci 2020;52:60–73, http://dx.doi.org/10.19106/JMedSci005203202007.
[17] Griñols Department of Public Affairs. Blood Plasma of Compensated Plasma Donation. Griñols Dep Public Aff 2014:1-1.
[18] WHO. WHO webinar on collection of COVID-19 convalescent plasma. WHO; 2020.
[19] Roback JD, Guerner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020;323:1561, http://dx.doi.org/10.1001/jama.2020.4940.
[20] WHO. Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (COVID-19) pandemic and on the collection of COVID-19 convalescent plasma. WHO; 2020.
[21] World Health Organization, International Federation of Red Cross, Red Crescent Societies. Towards 100% voluntary blood donation: a global framework for action; 2010.
[22] ISBT. A Code of Ethics for Blood Donation and Transfusion. ISBT 2011:1-12-9.
[23] WHO. Ethics of using convalescent whole blood and convalescent plasma during the Ebola epidemic. Interim guidance for ethics review committees, researchers, national health authorities and blood transfusion services. Switzerland: World Health Organization (WHO); 2015.
[24] World Health Organization. Blood Donor Selection. Switzerland: WHO; 2012.
[25] Hantavirus Study Grup in Chile, et al. A non-randomized multi-centre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome by ANDV. Antivir Ther 2014;20:377–86, http://dx.doi.org/10.3851/IMP2675.
[26] Kemensrian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia, Nomor 36 tahun 2012 Tentang Rahasia kedeokteran. Jakarta: KEMENKES RI; 2012.
[27] Design guidelines for blood centres. Manila, Philippines: World Health Organization. Western Pacific Region; 2010.
[28] Folléa G, Seifried E, de Wit J. Renewed considerations on ethical values for blood and plasma donations and donors. Blood Transfus 2014;12:387–93, http://dx.doi.org/10.2450/2013.0011-13.
[29] Council for International Organizations of Medical Sciences. In: World Health Organization, editor. International ethical guidelines for biomedical research involving human subjects. Geneva: CIOMS; 2002.
[30] WHO. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks. In: Interim Guidance for National Health Authorities and Blood Transfusion Services. Switzerland: World Health Organization (WHO); 2012.
[31] Holm S. Principles of Biomedical Ethics, 5th edn.: Beauchamp T L, Childress J F. Oxford University Press, 2001, pound19.95, pp 454. ISBN 0-19-514332-0. J Med Ethics 2002;28, http://dx.doi.org/10.1136/jme.28.5.332-a [332-a-332].
[32] Bazaar J, Farrokh M, Khankhe H. Triage systems in mass casualty incidents and disasters: a review study with a worldwide approach. Open Access Maced J Med Sci 2019;7:482–94, http://dx.doi.org/10.3889/oamjms.2019.119.